177Lu-PSMA 的有效半衰期、排泄和辐射暴露

EFFECTIVE HALF-LIFE, EXCRETION AND RADIATION EXPOSURE OF 177LU-PSMA.

机构信息

Department of Nuclear Medicine, School of Medicine, Manisa Celal Bayar University, Uncubozkoy, 45030 Manisa, Turkey.

出版信息

Radiat Prot Dosimetry. 2023 Jun 23;199(10):1090-1095. doi: 10.1093/rpd/ncad141.

Abstract

The study aims to evaluate the radiation safety conditions by detecting the patient's urine excretion rate, calculating the effective half-life, and determining the retention of 177Lu-PSMA in the body. Urine samples of patients were collected for 24 hours (6, 12, 18, and 24 hours) following the infusion, excretion rate and retention of 177Lu-PSMA in the body of patients were calculated. The measurements of dose rate were performed. Effective half-life calculated from dose rate measurements was found as 18.5 ± 11 h within the first 24 h and 48.1 ± 22.8 h between 24 and 72 h. Excreted activity in urine was found as 33.8 ± 20.7, 40.4 ± 20.3, 46.1 ± 22.4, and 53.3 ± 21.5% of total doses at 6, 12, 18, and 24 h after administration, respectively. External dose rates for 4 h and 24 h were 24.51 μSv/h, 16.14 μSv/h, respectively. Our results showed that 177Lu-PSMA treatment was suitable for outpatient treatment in terms of radiation safety.

摘要

本研究旨在通过检测患者的尿液排泄率、计算有效半衰期和确定 177Lu-PSMA 在体内的滞留来评估辐射安全性。在输注后 6、12、18 和 24 小时收集患者的尿液样本，计算患者体内 177Lu-PSMA 的排泄率和滞留率。进行剂量率测量。从剂量率测量中计算出的有效半衰期在前 24 小时内为 18.5 ± 11 小时，在 24 至 72 小时之间为 48.1 ± 22.8 小时。在给药后 6、12、18 和 24 小时，尿液中排泄的活性分别为总剂量的 33.8 ± 20.7%、40.4 ± 20.3%、46.1 ± 22.4%和 53.3 ± 21.5%。4 小时和 24 小时的外剂量率分别为 24.51 μSv/h 和 16.14 μSv/h。我们的结果表明，177Lu-PSMA 治疗在辐射安全性方面适合门诊治疗。